A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
NCT02662634
Withdrawn
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/03/2022
Locations: Cancer Research Network of Nebraska / Oncology Associates, Omaha, Nebraska
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NCT03278626
Terminated
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care established by the CROSS trial: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: University of Califonia, San Diego, La Jolla, California +4 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
Trial of NanoPac Focal Therapy for Prostate Cancer
NCT04221828
Terminated
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: Moffitt Cancer Center, Tampa, Florida +3 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm, Urogenital Neoplasms, Genital Neoplasms, Male, Localized Cancer
Register for Updates
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
NCT03486314
Completed
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Emory University, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Neoplasm
Register for Updates
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
NCT02810457
Completed
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2022
Locations: Research Site 7814 - Compassionate Care Research Group, Fountain Valley, California +146 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
NCT00393068
Completed
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal cancer. Side effects (toxicity) information will also be collected.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2022
Locations: Florida Cancer Specialists, Fort Myers, Florida +8 locations
Conditions: Esophageal Cancer
Register for Updates
Pembro/Carbo/Taxol in Endometrial Cancer
NCT02549209
Completed
This is a single-arm, open-label, multi-center phase II study for subjects with measurable advanced or recurrent endometrial cancer using pembrolizumab in combination with carboplatin and paclitaxel chemotherapy. As this combination of agents has not been tested in this subject population, the first six subjects enrolled will constitute a safety run-in cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Ironwood Cancer and Research Centers, Mesa, Arizona +5 locations
Conditions: Endometrial Cancer, Endometrial Adenocarcinoma
Register for Updates
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
NCT02810418
Completed
Background: LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by a very small number of normal tissues. Other cancers that make mesothelin include mesothelioma, cholangiocarcinoma, thymic carcinoma, ovarian, lung, gastric, endometrial, cervical, and ampullary cancers. After binding to the mesothelin on tumors, LMB-100 can attack and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Pancreatic Neoplasms
Register for Updates
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
NCT03067610
Completed
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/16/2022
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
Register for Updates
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
NCT02970539
Unknown
This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2022
Locations: CTRC-UT, San Antonio, Texas +4 locations
Conditions: Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
Register for Updates
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
NCT01515306
Completed
The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as mon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2022
Locations: ImClone Investigational Site, Ann Arbor, Michigan +5 locations
Conditions: Malignant Solid Tumor
Register for Updates
Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease
NCT04647643
Completed
Treatment with paclitaxel-based endovascular devices (PED) has become a common treatment option for patients with peripheral artery disease (PAD) involving the femoral-popliteal artery. However, an aggregate level meta-analysis identified an association between the use of PED and increased all-cause mortality at both two and five-year follow-up intervals, though there are significant limitations of these analyses. Exploration of real-world data has been suggested as a means to further investigat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2022
Locations: Lahey Clinic, Inc, Burlington, Massachusetts
Conditions: Peripheral Arterial Disease
Register for Updates